Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been
tested in advanced melanoma patients at various centers. We conducted a systematic …

Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …

Purpose: Adoptive cell transfer therapy (ACT) based on autologous tumor-infiltrating
lymphocytes (TIL) has achieved impressive clinical results in several phase I and II trials …

Background Adoptive cell therapy may be based on isolation of tumor-specific T cells, eg
autologous tumor infiltrating lymphocytes (TIL), in vitro activation and expansion and the …

Purpose: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating
Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma - PMC Back to Top Skip to …

Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating
lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s …

Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is
a promising treatment for metastatic melanoma unresponsive to conventional therapies. We …

Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes
(TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but …

Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown
significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion …